Yongcheng Song

Prof. Yongcheng Song


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2020 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
Xin LiXin Li
Xin Li
YSYongcheng Song
Yongcheng Song
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of the protein of interest (POI) and a covalently linked ligand of an E3 ubiquitin ligase (E3). Upon binding to the POI, the PROTAC can recruit E3 for POI ubiquitination, which is subjected to proteasome-mediated degradation. PROTAC complements nucleic acid-based gene knockdown/out technologies for targeted protein reduction and could mimic pharmacological protein inhibition. To date, PROTACs targeting ~ 50 proteins, many of which are clinically validated drug targets, have been successfully developed with several in clinical trials for cancer therapy. This article reviews PROTAC-mediated degradation of critical oncoproteins in cancer, particularly those in hematological malignancies. Chemical structures, cellular and in vivo activities, pharmacokinetics, and pharmacodynamics of these PROTACs are summarized. In addition, potential advantages, challenges, and perspectives of PROTAC technology in cancer therapy are discussed.

17 June 2016 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
YSYongcheng Song
Yongcheng Song
FWFangrui Wu
Fangrui Wu
JWJingyu Wu
Jingyu Wu
Post-translational methylation of histone lysine or arginine residues plays important roles in gene regulation and other physiological processes. Aberrant histone methylation caused by a gene mutation, translocation, or overexpression can often lead to initiation of a disease such as cancer. Small molecule inhibitors of such histone modifying enzymes that correct the abnormal methylation could be used as novel therapeutics for these diseases, or as chemical probes for investigation of epigenetics. Discovery and development of histone methylation modulators are in an early stage and undergo a rapid expansion in the past few years. A number of highly potent and selective compounds have been reported, together with extensive preclinical studies of their biological activity. Several compounds have been in clinical trials for safety, pharmacokinetics, and efficacy, targeting several types of cancer. This review summarizes the biochemistry, structures, and biology of cancer-relevant histone methylation modifying enzymes, small molecule inhibitors and their preclinical and clinical antitumor activities. Perspectives for targeting histone methylation for cancer therapy are also discussed.

21 September 2011 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YYYuan Yao
Yuan Yao
PCPinhong Chen
Pinhong Chen
JDJiasheng Diao
Jiasheng Diao
CGCheng Gang
Cheng Gang
LDLisheng Deng
Lisheng Deng
YSYongcheng Song
Yongcheng Song

23 April 2019 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YYYuan Yao
Yuan Yao
THTong Huo
Tong Huo
YLYi-Lun Lin
Yi-Lun Lin
SNShenyou Nie
Shenyou Nie
FWFangrui Wu
Fangrui Wu
YSYongcheng Song
Yongcheng Song

12 March 2016 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
ZFZizhen Feng
Zizhen Feng
YYYuan Yao
Yuan Yao
CZChao Zhou
Chao Zhou
FCFengju Chen
Fengju Chen
FWFangrui Wu
Fangrui Wu
YSYongcheng Song
Yongcheng Song
Mixed lineage leukemia (MLL) gene translocations are found in ~75 % infant and 10 % adult acute leukemia, showing a poor prognosis. Lysine-specific demethylase 1 (LSD1) has recently been implicated to be a drug target for this subtype of leukemia. More studies using potent LSD1 inhibitors against MLL-rearranged leukemia are needed. LSD1 inhibitors were examined for their biochemical and biological activities against LSD1 and MLL-rearranged leukemia as well as other cancer cells. Potent LSD1 inhibitors with biochemical IC50 values of 9.8–77 nM were found to strongly inhibit proliferation of MLL-rearranged leukemia cells with EC50 of 10–320 nM, while these compounds are generally non-cytotoxic to several other tumor cells. LSD1 inhibition increased histone H3 lysine 4 (H3K4) methylation, downregulated expression of several leukemia-relevant genes, induced apoptosis and differentiation, and inhibited self-renewal of stem-like leukemia cells. Moreover, LSD1 inhibitors worked synergistically with inhibition of DOT1L, a histone H3 lysine 79 (H3K79) methyltransferase, against MLL-rearranged leukemia. The most potent LSD1 inhibitor showed significant in vivo activity in a systemic mouse model of MLL-rearranged leukemia without overt toxicities. Mechanistically, LSD1 inhibitors caused significant upregulation of several pathways that promote hematopoietic differentiation and apoptosis. LSD1 is a drug target for MLL-rearranged leukemia, and LSD1 inhibitors are potential therapeutics for the malignancy.

10 November 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
LZLi Zhang
Li Zhang
LDLisheng Deng
Lisheng Deng
FCFengju Chen
Fengju Chen
YYYuan Yao
Yuan Yao
BWBulan Wu
Bulan Wu
YSYongcheng Song
Yongcheng Song
Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer